Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRADA: Trabectedin vs doxorubicin plus dacarbazine in advanced solitary fibrous tumor
2016-004051-78Phase 2Completed
- Sponsor
- Italian Sarcoma Group
- Start
- Aug 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hemangiopericytoma (HPC) and soft tissue sarcoma (STS) comparing Trabectedin with Doxorubicin plus dacarbazine (2 arms). Primary endpoint: Objective response rate at 6 weeks by RECIST 1.1. Started Aug 2021; status: completed.
02
Drugs
trabectedindoxorubicindacarbazine
03
Conditions
hemangiopericytoma (HPC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2016-004051-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004051-78.